General Information |
Board Constituency: |
None |
Is your organization legally registered in your country: |
Yes |
If yes, please enter your registration number: |
2068285-4 |
Organization Type - Primary: |
Private Sector |
Organization Type - Secondary: |
Company |
Organization Description: |
We are a clinical-stage biopharmaceutical company focusing on immuno-oncology, organ trauma and vascular damage. Since 2007 our goal has been to develop unique scientific discoveries into ground-breaking new treatments for hard-to-treat and rare diseases. To save lives. We have an interest in continuing to develop our assets into more hard to treat indications, TB is one of these. We are planning to bring the first immunotherapy to TB and rather than control TB, eradicate it. |
|
Do you know about the UNHLM declaration: |
No |
Other Organization Information |
Total number of staff in your organization: |
11 - 25 |
Number of full-time staff who are directly involved with TB: |
1 - 5 |
Number of part-time staff who are directly involved with TB: |
0 |
Number of volunteers who are directly involved with TB: |
0 |
|
How did you hear about the Stop TB Partnership: |
Internet search |
If you were informed or referred by another partner of the Stop TB Partnership please tell us who: |
|
Why do you wish join the Stop TB Partnership: |
Involvement in Stop TB Working Groups |
|
Are you a member of a Stop TB national partnership: |
No |
Are you in contact with your national TB programme: |
Yes |
Please tell us how your organization is contributing to your country's national TB control plan: |
We are currently in discussions with Finland's national TB programme to eradicate both active and latent TB |
|
Geographical Reach |
Which country is your headquarters located in: |
Finland |
Which countries do you do operate in: (This includes countries you are conducting activities in) |
Switzerland |